Exabis Library
Welcome to the e-CCO Library!
P485: Apolipoprotein C3 is Downregulated in Patients with Inflammatory Bowel Disease
2022
ECCO'22
Friday, 11 February 2022, 3:56 PM
P485: Development and implementation of a remote monitoring tool for real-world assessment of mild, moderate and severe infectious complications in Inflammatory Bowel Disease patients
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P485: Dosing infliximab in Crohn's disease: Is adjustment for body size justified?
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P485: Prediction Model Incorporating Pharmacokinetics Calculates Probability of Endoscopic Healing in Patients with ulcerative colitis Starting Infliximab Therapy
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P485: Real-world evidence (RWE) on outcomes and clinical treatment patterns of 5-aminosalicylic acid (5-ASA) in mild Crohn’s disease (CD) from European healthcare databases (the CROHN’S investigation)
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P485: The combined of mesenchymal stem cells and infliximab reduces the recurrence rate of Crohn’s disease
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
P486 Assessing the efficacy of biologics in ucerative colitis: a real-life, observational retrospective multicentre study with propensity score analysis (AURORA): Focus on patients naive to biologics
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P486: Faecal microbiota transplantation in inflammatory bowel disease: the patient's perspective
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P486: Immunization status of children and adolescents with inflammatory bowel disease or autoimmune hepatitis in Germany
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P486: Improving enhanced recovery after surgery (ERAS): the effect of a patient-centred mobile application on patient participation in colorectal surgery
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P486: Intrapatient variability in adalimumab drug levels within and across cycles in Crohn’s disease
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
P486: Iron deficiency anaemia in inflammatory bowel disease: Diagnosis, quality of life and iron treatment preferences among European patients
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P486: Response to vedolizumab therapy in patients with inflammatory bowel disease: Impact of drug levels, anti-drug antibodies and α4β7 target occupancy
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P486: Treatment-emergent COVID-19 infections in ozanimod ulcerative colitis and multiple sclerosis clinical trials
2022
ECCO'22
Friday, 11 February 2022, 3:56 PM
P487 Development and validation of a new patient-reported outcome measure for Crohn’s perianal fistula: Crohn’s anal fistula quality-of-life (CAF-QoL) scale
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P487: Anti TNF induced psoariasiform skin eruptions are increasing in in the biosimilar era – a descriptive study of drug induced skin manifestations and their management
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P487: Early vedolizumab trough levels are not associated with a short-term response in patients with inflammatory bowel disease
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P487: Effectiveness and safety of CT-P13 under routine care in paediatric patients with inflammatory bowel disease
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P487: Surgery due to inflammatory bowel disease during pregnancy: mothers and offspring outcomes (SCAR Study)
2022
ECCO'22
Friday, 11 February 2022, 3:56 PM
P487: The effect of a coordinated care programme for inflammatory bowel diseases on health care utilisation
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM